Protein kinase inhibitors

US10391082B2 · kind B2 · utility

Assignee

• ORION CORPORATION · FI

Inventors

• Tero LINNANEN · Tuusula, FI
• Gerd Wohlfahrt · Helsinki, FI
• Srinivas Nanduri · Hyderabad, IN
• Ravi Ujjinamatada · Anekal, IN
• Srinivasan Rajagopalan · Bengaluru, IN
• Subhendu Mukherjee

Key dates

• Filing date: May 7, 2018
• Grant date: Aug 27, 2019
• Expiry date: May 7, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.